Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 5/20 | 0.59 |
| ▸ | ACHE | P22303 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569771 | 0.90 | TSHR (0.69) | TSHRATMMEN1KMT2ABCHE | |
| SCHEMBL14569696 | 0.88 | TSHR (0.66) | TSHRATMMEN1KMT2ABCHE | |
| SCHEMBL6335583 | 0.86 | MAOB (0.60) | TSHRMAOBMEN1KMT2ABCHE | |
| SCHEMBL14087166 | 0.86 | MAOB (0.63) | MAOBKMT2ABCHEACHESMN1; SMN2 | |
| SCHEMBL4877516 | 0.85 | TSHR (0.63) | TSHRATMMAOBMEN1KMT2A | |
| SCHEMBL20249532 | 0.85 | TSHR (0.63) | TSHRATMMEN1KMT2ABCHE | |
| SCHEMBL16384274 | 0.85 | TSHR (0.66) | TSHRATMMAOBMEN1KMT2A | |
| SCHEMBL4876506 | 0.84 | TSHR (0.57) | TSHRATMMEN1KMT2ABCHE | |
| SCHEMBL17682060 | 0.83 | TSHR (0.81) | TSHRATMMAOBMEN1KMT2A | |
| SCHEMBL15226786 | 0.82 | TSHR (0.75) | TSHRATMMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1819669-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | HDAC1, HDAC10, HDAC6 | TSHR 3237/4885ATM 2436/4885MAOB 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.